ResMed CEO Michael J. Farrell Exercises Options, Sells Shares

What Happened Michael J. Farrell, Chairman and CEO of ResMed Inc. (RMD), exercised 4,991 stock options and then sold the resulting 4,991 shares on Sept 8, 2026. The exercise recorded an acquisition cost of $146.34 per share (total $730,383). The shares were sold in the open market at a weighted-average price of $222.44 per share for total proceeds of $1,110,191, producing gross proceeds roughly $379,808 above the exercise cost. The filing shows the exercise/conversion of the derivative and immediate sale of the shares (cashless-style transaction), which is typically a routine way for executives to monetize option gains.

Key Details

• Transaction date: 2026-09-08 (reported on Form 4 filed 2026-09-10; timely filing)
• Exercise: 4,991 shares at $146.34 each = $730,383 (code M)
• Sale: 4,991 shares sold at weighted-average $222.44 = $1,110,191 (code S)
• Sale execution: multiple trades at prices ranging $220.680 – $225.390 (footnote F2)
• Derivative line: 4,991 shares shown as disposed at $0 reflecting conversion of the derivative into shares (as reported)
• Plan/footnotes: Transaction was executed under a Rule 10b5-1 trading plan adopted Oct 31, 2024 (F1); options vest 1/3 per year and the footnote (F3) references the date options first became exercisable
• Shares owned after transaction: not specified in the provided summary of the filing

Context Because the exercise and sale occurred together under a pre-arranged 10b5-1 plan, this reads as a planned monetization of vested options rather than a discretionary, out-of-plan trade. For retail investors, purchases can signal confidence, while routine option exercises followed by immediate sales are common ways executives realize gains and do not necessarily indicate a change in outlook.